# US 2021/0330611 A1 · Therapy for neurological diseases/disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330611 A1
- Document ID: US20210330611A1
- Status: Published application
- Kind: A1
- Application number: 17/229,394
- Filed: 2021-04-13
- Published: 2021-10-28
- Earliest claimed: 2020-04-13
- Inventors: Katerina Akassoglou; Anke Meyer-Franke; Alex Pico; Kean-Hooi Ang; Michelle Rose Arkin
- Web page: https://patentgrep.com/patent/US20210330611A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/365: Lactones
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/7024: Esters of saccharides
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compositions and methods to treat or prevent neurodegeneration in a mammal, inhibit microglial activation in the CNS of a mammal, promote survival of CNS neurons in a mammal, prevent or reduce the rate of demyelination and/or neuronal injury in a mammal, promote remyelination in a mammal and/or treat or prevent or decrease oxidative stress in a mammal.

## Claims

### Claim 1

A method to treat or prevent neurodegeneration in a mammal comparing administering to said mammal an effect amount of a composition comprising a modulator of calcium signaling, a modulator of microtubule dynamics, a modulator of chemokine signaling, a modulator of DNA replication, a modulator of dopamine receptor signaling, a modulator of cAMP signaling, a modulator of glucocorticoid-receptor signaling, a modulator of purine nucleotide biosynthesis, a modulator of neurotransmitter transport or a combination thereof or one or more of the small molecules provided in Table 1 and/or Table 2, provided that the small molecule is not acivicin.

### Claim 2

A method for inhibiting microglial activation in the CNS of a mammal and/or promoting survival of CNS neurons in a mammal, comprising administering to a mammal in need thereof an effective amount of a composition comprising a modulator of calcium signaling, a modulator of microtubule dynamics, a modulator of chemokine signaling, a modulator of DNA replication, a modulator of dopamine receptor signaling, a modulator of cAMP signaling, a modulator of glucocorticoid-receptor signaling, a modulator of purine nucleotide biosynthesis, a modulator of neurotransmitter transport or a combination thereof.

### Claim 3

A method for preventing or reducing the rate of demyelination and/or neuronal injury in a mammal and/or promoting remyelination in a mammal and/or treating or preventing or decreasing oxidative stress in a mammal in need thereof comprising administering to the mammal an effective amount of a modulator of calcium signaling, a modulator of microtubule dynamics, a modulator of chemokine signaling, a modulator of DNA replication, a modulator of dopamine receptor signaling, a modulator of cAMP signaling, a modulator of glucocorticoid-receptor signaling, a modulator of purine nucleotide biosynthesis, a modulator of neurotransmitter transport or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the modulator of calcium signaling is a calcium channel blocker, a vasodilator or an adrenoreceptor agonist.

### Claim 5 (depends on 4)

The method of claim 4, wherein the calcium channel blocker comprises fendiline.

### Claim 6 (depends on 4)

The method of claim 4, wherein the vasodilator comprises nylidrin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the modulator of microtubule dynamics is an inhibitor of microtubule assembly.

### Claim 8 (depends on 7)

The method of claim 7, wherein the inhibitor of microtubule assembly comprises vinblastine, colchicine and/or podofilox.

### Claim 9 (depends on 1)

The method of claim 1, wherein the modulator of chemokine signaling comprises tannic acid.

### Claim 10 (depends on 1)

The method of claim 1, wherein the modulator of DNA replication is an inhibitor of DNA topoisomerase II.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inhibitor of DNA topoisomerase II comprises teniposide.

### Claim 12 (depends on 1)

The method of claim 1, wherein the modulator of dopamine receptor signaling is blocker of dopamine receptors.

### Claim 13 (depends on 12)

The method of claim 12, wherein the blocker of dopamine receptors comprises prochlorperazine or thioridazine.

### Claim 14 (depends on 1)

The method of claim 1, wherein the modulator of cAMP signaling comprises nylidrin, prochlorperazine or thioridazine.

### Claim 15 (depends on 1)

The method of claim 1, wherein the modulator of glucocorticoid-receptor signaling comprises betamethasone, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, fludrocortisone acetate, fluocinolone acetonide, fluocinonide, fluorometholone, flurandrenolide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone hemisuccinate, hydrocortisone sodium phosphate, methylprednisolone, prednisolone or triamcinolone diacetate.

### Claim 16 (depends on 1)

The method of claim 1, wherein the modulator of purine nucleotide biosynthesis is an inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH).

### Claim 17 (depends on 16)

The method of claim 16, wherein the inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH) comprises mycophenolic acid (MPA).

### Claim 18 (depends on 1)

The method of claim 1, wherein the modulator of neurotransmitter transport is an inhibitor of norepinephrine reuptake.

### Claim 19 (depends on 18)

The method of claim 18, wherein the inhibitor of norepinephrine reuptake is maprotiline.

### Claim 20 (depends on 1)

The method of claim 1, wherein said mammal has been diagnosed with a disease, disorder, or injury involving demyelination, dysinyelination, or neurodegeneration.
